{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:33:51Z","timestamp":1788190431323,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We performed a national population-based study of all patients diagnosed with diffuse large B-cell lymphoma (DLBCL) in Sweden in 2007\u20132014 to assess treatment intent and risk of relapsed\/refractory disease, including central nervous system (CNS) relapse, in the presence of competing risks. Overall, 84% of patients started treatment with curative intent (anthracycline-based) (<jats:italic>n<\/jats:italic>\u2009=\u20093550, median age 69 years), whereas 14% did not (<jats:italic>n<\/jats:italic>\u2009=\u2009594, median age 84 years) (for 2% the intent was uncertain). Patients treated with curative intent had a 5-year OS of 65.3% (95% CI: 63.7\u201366.9). The median OS among non-curatively treated patients was 2.9 months. The 5-year cumulative incidence of relapsed\/refractory disease in curative patients was 23.1% (95% CI: 21.7\u201324.6, <jats:italic>n<\/jats:italic>\u2009=\u2009847). The 2-year cumulative incidence of CNS relapse was 3.0% (95% CI: 2.5\u20133.6, <jats:italic>n<\/jats:italic>\u2009=\u2009118) overall, and 8.0% (95% CI: 6.0\u201310.6, <jats:italic>n<\/jats:italic>\u2009=\u200948) among patients with high CNS-IPI (4\u20136), when considering other relapse locations and death as competing events. The incidence of relapsed\/refractory DLBCL overall and in the CNS was lower than in previous reports, still one in seven patients was not considered fit enough to start standard immunochemotherapy at diagnosis. These results are important for quantification of groups of DLBCL patients with poor prognosis requiring completely different types of interventions.<\/jats:p>","DOI":"10.1038\/s41408-020-00403-1","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T20:03:40Z","timestamp":1610049820000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Incidence of relapsed\/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4955-4728","authenticated-orcid":false,"given":"Sara","family":"Harrysson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Eloranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ekberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunilla","family":"Enblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4509-6707","authenticated-orcid":false,"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn E.","family":"Wahlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Ola","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin E.","family":"Smedby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"403_CR1","first-page":"393","volume":"60","author":"CR Flowers","year":"2010","unstructured":"Flowers, C. R., Sinha, R. & Vose, J. M. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin 60, 393\u2013408 (2010).","journal-title":"CA Cancer J Clin"},{"key":"403_CR2","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier, B. et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood. 116, 2040\u20132045 (2010).","journal-title":"Blood."},{"key":"403_CR3","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh, M. et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 12, 1013\u201322 (2011).","journal-title":"Lancet Oncol."},{"key":"403_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh, M. et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 9, 105\u2013116 (2008).","journal-title":"Lancet Oncol."},{"key":"403_CR5","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","volume":"24","author":"TM Habermann","year":"2006","unstructured":"Habermann, T. M. et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin. Oncol. 24, 3121\u20133127 (2006).","journal-title":"J Clin. Oncol."},{"key":"403_CR6","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","volume":"23","author":"LH Sehn","year":"2005","unstructured":"Sehn, L. H. et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. Journal Clin. Oncol. 23, 5027\u201333 (2005).","journal-title":"Journal Clin. Oncol."},{"key":"403_CR7","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht, C. et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J. Clin. Oncol. 28, 4184\u201390 (2010).","journal-title":"J. Clin. Oncol."},{"key":"403_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3324\/haematol.2018.195834","volume":"104","author":"D Qualls","year":"2019","unstructured":"Qualls, D. & Abramson, J. S. Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma. Haematologica. 104, 25\u201334 (2019).","journal-title":"Haematologica."},{"key":"403_CR9","doi-asserted-by":"crossref","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N. Engl. J. Med. 329, 987\u2013994 (1993).","DOI":"10.1056\/NEJM199309303291402"},{"key":"403_CR10","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","volume":"34","author":"N Schmitz","year":"2016","unstructured":"Schmitz, N. et al. CNS International Prognostic Index: a risk model for cns relapse in patients with diffuse large b-cell lymphoma treated with R-CHOP. J. Clin. Oncol. 34, 3150\u20133156 (2016).","journal-title":"J. Clin. Oncol."},{"key":"403_CR11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503\u201311 (2000).","journal-title":"Nature"},{"key":"403_CR12","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald, A. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 1937\u20131947 (2002).","journal-title":"N. Engl. J. Med."},{"key":"403_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nm0102-68","volume":"8","author":"MA Shipp","year":"2002","unstructured":"Shipp, M. A. et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. 8, 68\u201374 (2002).","journal-title":"Nat. Med."},{"key":"403_CR14","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy, B. et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 24, 679\u201390 (2018).","journal-title":"Nat. Med."},{"key":"403_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","volume":"560","author":"JD Phelan","year":"2018","unstructured":"Phelan, J. D. et al. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. 560, 387\u201391 (2018).","journal-title":"Nature."},{"key":"403_CR16","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood.2019003535","volume":"135","author":"SE Lacy","year":"2020","unstructured":"Lacy, S. E. et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood. 135, 1759\u20131771 (2020).","journal-title":"Blood."},{"key":"403_CR17","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","volume":"2011","author":"JW Friedberg","year":"2011","unstructured":"Friedberg, J. W. Relapsed\/refractory diffuse large B-cell lymphoma. Hematology Am. Soc. Hematol. Educ. Program 2011, 498\u2013505 (2011).","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"403_CR18","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","volume":"32","author":"MJ Maurer","year":"2014","unstructured":"Maurer, M. J. et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J. Clin. Oncol. 32, 1066\u201373 (2014).","journal-title":"J. Clin. Oncol."},{"key":"403_CR19","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump, M. et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 130, 1800\u20131808 (2017).","journal-title":"Blood."},{"key":"403_CR20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3747\/co.26.5421","volume":"26","author":"P Skrabek","year":"2019","unstructured":"Skrabek, P. et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Curr. Oncol. (Toronto, Ont) 26, 253\u2013265 (2019).","journal-title":"Curr. Oncol. (Toronto, Ont)"},{"key":"403_CR21","first-page":"1385","volume":"24","author":"H Holte","year":"2013","unstructured":"Holte, H. et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell\/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Annals of oncology: official journal of the European Society for. Med. Oncol. 24, 1385\u20131392 (2013).","journal-title":"Med. Oncol."},{"key":"403_CR22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson, B. D. et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25, 579\u201386 (2007).","journal-title":"J. Clin. Oncol."},{"key":"403_CR23","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","volume":"35","author":"U Vitolo","year":"2017","unstructured":"Vitolo, U. et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J. Clin. Oncol. 35, 3529\u201337 (2017).","journal-title":"J. Clin. Oncol."},{"key":"403_CR24","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1182\/blood-2008-10-182253","volume":"113","author":"V Boehme","year":"2009","unstructured":"Boehme, V., Schmitz, N., Zeynalova, S., Loeffler, M. & Pfreundschuh, M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 113, 3896\u2013902 (2009).","journal-title":"Blood."},{"key":"403_CR25","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.3324\/haematol.2019.229948","volume":"105","author":"TA Eyre","year":"2020","unstructured":"Eyre, T. A., Djebbari, F., Kirkwood, A. A. & Collins, G. P. A systematic review of the efficacy of CNS prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era. Haematologica. 105, 1914\u20131924 (2020).","journal-title":"Haematologica"},{"key":"403_CR26","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/ejh.13068","volume":"100","author":"KC Lakshmaiah","year":"2018","unstructured":"Lakshmaiah, K. C. et al. Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B-cell lymphoma. Eur. J. Haematol. 100, 644\u2013648 (2018).","journal-title":"Eur. J. Haematol."},{"key":"403_CR27","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh, M. et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 104, 634\u2013641 (2004).","journal-title":"Blood."},{"key":"403_CR28","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","volume":"12","author":"F Peyrade","year":"2011","unstructured":"Peyrade, F. et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 12, 460\u2013468 (2011).","journal-title":"Lancet Oncol."},{"key":"403_CR29","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S1470-2045(19)30091-9","volume":"20","author":"H Tilly","year":"2019","unstructured":"Tilly, H. et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Lancet Oncol. 20, 998\u20131010 (2019).","journal-title":"Lancet Oncol."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00403-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00403-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00403-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T15:38:47Z","timestamp":1669909127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00403-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["403"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-00403-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"11 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was financed partly through the Swedish Cancer Society and partly through a public\u2013private real-world evidence collaboration between Karolinska Institutet and Janssen Pharmaceutical NV. The funding bodies supported the data collection but did not have a role in the study design, data analyses or manuscript writing\/decision to publish. Drs. Harrysson, Eloranta, Ekberg, Enblad, Jerkeman, Wahlin, Andersson, Smedby have nothing further to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"9"}}